This trade activity should not be overlooked: EyePoint Pharmaceuticals Inc (EYPT)

With 0.97 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.03 million shares. The 52-week range on EYPT shows that it touched its highest point at $30.99 and its lowest point at $2.87 during that stretch. It currently has a 1-year price target of $45.11. Beta for the stock currently stands at 1.66.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EYPT was down-trending over the past week, with a drop of -8.94%, but this was down by -25.51% over a month. Three-month performance dropped to -13.96% while six-month performance rose 153.38%. The stock gained 496.18% in the past year, while it has lost -12.29% so far this year. A look at the trailing 12-month EPS for EYPT yields -1.84 with Next year EPS estimates of -2.53. For the next quarter, that number is -0.39. This implies an EPS growth rate of 3.13% for this year and -43.57% for next year.

Float and Shares Shorts:

At present, 49.04 million EYPT shares are outstanding with a float of 46.59 million shares on hand for trading. On Mar 15, 2024, short shares totaled 6.58 million, which was 13.20% higher than short shares on Feb 15, 2024. In addition to Dr. Jay S. Duker M.D. as the firm’s President, CEO & Director, Dr. John B. Landis M.S., Ph.D. serves as its Interim Head of R&D and Director.

Institutional Ownership:

Through their ownership of 104.03% of EYPT’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EYPT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, EYPT has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and EYPT currently yields $0.00. In the past year, EYPT’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, EYPT has a current buyback yield of $––. This was $–– for the TTM, and it was $–– for the past five years.